![\"\"\/](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/06\/1782279912_778_ex99-1_001.jpg\")
<\/p>\n\u00a0<\/p>\n
\u00a0<\/p>\n
UNITED
\nSTATES<\/p>\n
SECURITIES
\nAND EXCHANGE COMMISSION<\/p>\n
Washington,
\nD.C. 20549<\/p>\n
\u00a0<\/p>\n
FORM
\n6-K<\/p>\n
\u00a0<\/p>\n
REPORT
\nOF FOREIGN PRIVATE ISSUER<\/p>\n
PURSUANT
\nTO RULE 13a-16 OR 15d-16<\/p>\n
UNDER
\nTHE SECURITIES EXCHANGE ACT OF 1934<\/p>\n
\u00a0<\/p>\n
For
\nthe month of June 2026<\/p>\n
\u00a0<\/p>\n
Commission
\nFile Number: 001-42915<\/p>\n
\u00a0<\/p>\n
Alps
\nGroup Inc<\/p>\n
(Registrant\u2019s
\nName)<\/p>\n
\u00a0<\/p>\n
Unit
\nE-18-01 & E-18-02, Level 18, Icon Tower (East)<\/p>\n
No.
\n1, Jalan 1\/68F, Jalan Tun Razak<\/p>\n
50400
\nKuala Lumpur<\/p>\n
Wilayah
\nPersekutuan, Malaysia<\/p>\n
(Address
\nof Principal Executive Offices)<\/p>\n
\u00a0<\/p>\n
Indicate
\nby check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.<\/p>\n
\u00a0<\/p>\n
Form
\n20-F \u2612 Form 40-F \u2610<\/p>\n
\u00a0<\/p>\n
Indicate
\nby check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \u2610<\/p>\n
\u00a0<\/p>\n
Indicate
\nby check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \u2610<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Information
\nContained in this Form 6-K Report<\/p>\n
\u00a0<\/p>\n
Attached
\nhereto as Exhibit 99.1 is a press release dated June 23, 2026 issued by Alps Group Inc (the \u201cCompany\u201d), announcing the launch
\nof patient-derived organoid program to advance personalized cancer care in Southeast Asia.<\/p>\n
\u00a0<\/p>\n
Exhibits<\/p>\n
\u00a0<\/p>\n
Exhibit
\n No.
\n \u00a0
\n Description<\/p>\n
99.1
\n \u00a0
\n Press Release dated June 23, 2026<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
SIGNATURES<\/p>\n
\u00a0<\/p>\n
Pursuant
\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
\nthe undersigned, thereunto duly authorized.<\/p>\n
\u00a0<\/p>\n
\u00a0
\n Alps
\n Group Inc<\/p>\n
\u00a0
\n \u00a0
\n \u00a0<\/p>\n
Date:
\n June 23, 2026
\n By:
\n \/s\/
\n Dr. Tham Seng Kong<\/p>\n
\u00a0
\n Name:<\/p>\n
Dr.
\n Tham Seng Kong<\/p>\n
\u00a0
\n Title:
\n Chief
\n Executive Officer and Director<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Exhibit
\n99.1<\/p>\n
\u00a0<\/p>\n
<\/p>\n
\u00a0<\/p>\n
Alps
\nGroup Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia<\/p>\n
\u00a0<\/p>\n
Agreement
\nMarks Company\u2019s Expansion into Precision Oncology Testing, with the Goal of Establishing Malaysia\u2019s First Clinically Validated
\nPDO Platform<\/p>\n
\u00a0<\/p>\n
KUALA
\nLUMPUR, Malaysia \u2013 June 23, 2026 \u2013 Alps Group Inc (\u201cAlps\u201d or \u201cthe Company\u201d) (Nasdaq: ALPS), an
\nintegrated biotechnology platform headquartered in Malaysia, today announced its expansion into patient-derived organoid (PDO) technology
\nthrough a Research and Collaboration Agreement with Dr. Kong Wai Mun, Executive Director of Axiocell Biotech and a biomedical scientist
\nwith more than 17 years of experience in translational research and preclinical model development.<\/p>\n
\u00a0<\/p>\n
Under
\nthe agreement, Alps is launching an internal PDO program targeting personalized cancer treatment and preclinical drug screening, a fast-growing
\nfield in precision oncology. According to Future Market Insights, the global human organoids market was valued at approximately USD 91.8
\nmillion in 2026 and is projected to reach USD 349.5 million by 2036, growing at a CAGR of 14.3%. The global personalized cancer treatment
\nmarket was valued at approximately USD 222.54 billion in 2026 and is projected to reach USD 332.37 billion by 2030, growing at a CAGR
\nof 10.5%.1 Alps aims to develop Malaysia\u2019s first clinically validated PDO platform with a defined regulatory pathway
\nthat includes obtaining MREC ethics approval and Medical Device Authority (MDA) regulatory registration to support clinical deployment
\nand commercialization.<\/p>\n
\u00a0<\/p>\n
PDO
\ntechnology involves growing three-dimensional \u201cmini-tumors\u201d from a patient\u2019s own cancer tissue, allowing clinicians
\nand researchers to evaluate how individual tumors may respond to different therapies. This approach is designed to improve treatment
\nselection, accelerate drug development, and reduce reliance on animal testing.<\/p>\n
\u00a0<\/p>\n
Alps
\nplans to establish a national PDO biobank to support preclinical drug screening and licensing services for pharmaceutical and CRO partners,
\nwith a long-term goal of positioning Malaysia as a regional hub for PDO-based translational research. The program has identified initial
\nclinical interest across six major oncology centers in Malaysia. According to GLOBOCAN 2022, Malaysia records approximately 51,650 new
\ncancer cases per year.2 The Malaysia National Cancer Registry Report further notes that 64.8% of cases are diagnosed at
\nadvanced stages.3<\/p>\n
\u00a0<\/p>\n
\u201cPDO
\ntechnology is a natural extension of Alps\u2019 integrated platform, bringing together our existing genomic, manufacturing, and clinical
\ncapabilities to deliver truly personalized oncology care,\u201d said Dr. Tham Seng Kong, Executive Director and Group Chief Executive
\nOfficer of Alps Group Inc. \u201cBy predicting how a patient\u2019s tumor responds to treatment before therapy begins, PDO technology
\nrepresents a meaningful step toward making advanced cancer care accessible and affordable for patients across Southeast Asia.\u201d<\/p>\n
\u00a0<\/p>\n
1
\n Organoids market: Future Market Insights, Organoids Market Report (2026\u20132036).
\n Global personalized cancer treatment market: The Business Research Company, Personalized
\n Cancer Treatment Global Market Report 2026.<\/p>\n
2
\nInternational Agency for Research on Cancer. Malaysia: GLOBOCAN 2022 Fact Sheet. World Health Organization.<\/p>\n
3
\nNational Cancer Registry Department, Institut Kanser Negara. Malaysia National Cancer Registry Report 2017\u20132021, p. 26.
\nMinistry of Health Malaysia, 2025.<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
<\/p>\n
\u00a0<\/p>\n
Kong
\nWai Mun, PhD, Executive Director of Axiocell Biotech, commented, \u201cPDO technology holds significant promise in bridging the gap
\nbetween laboratory research and clinical application. By enabling clinicians and researchers to evaluate how a patient\u2019s tumor
\nmay respond to treatment before therapy is administered, PDO platforms have the potential to support more personalized approaches to
\ncancer care. PDOs also serve as a powerful preclinical platform for translational research and can function as a form of early clinical
\ntrial simulation. This program represents an important step for precision oncology research in Malaysia, one that builds on world-class
\nclinical expertise already present in the country while creating the infrastructure needed to translate that expertise into better outcomes
\nfor patients.\u201d<\/p>\n
\u00a0<\/p>\n
To
\nbe added to the Alps Group Inc email distribution list, please email Alps@kcsa.com with ALPS in the subject line.<\/p>\n
\u00a0<\/p>\n
About
\nAlps Group Inc<\/p>\n
\u00a0<\/p>\n
Alps
\nGroup Inc is a revenue-generating integrated biotechnology platform headquartered in Malaysia, operating across cell manufacturing, molecular
\ndiagnostics, and clinical delivery. Alps leverages revenue from its commercial businesses to support its clinical pipeline development,
\nwith a mission to make advanced precision medicine accessible and affordable across Southeast Asia.<\/p>\n
\u00a0<\/p>\n
Forward-Looking
\nStatements<\/p>\n
\u00a0<\/p>\n
Certain
\nstatements in this press release may be considered to contain certain \u201cforward-looking statements\u201d within the meaning of
\n\u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified
\nby words such as: \u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201cwill,\u201d \u201cshall,\u201d \u201cmay,\u201d
\n\u201canticipate,\u201d \u201cestimate,\u201d \u201cwould,\u201d \u201cpositioned,\u201d \u201cfuture,\u201d \u201cforecast,\u201d
\n\u201cintend,\u201d \u201cplan,\u201d \u201cproject\u201d and other similar expressions that predict or indicate future events
\nor trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of
\nfuture performance. Instead, they are based only on the Company management\u2019s current beliefs, expectations, and assumptions. Because
\nforward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that
\nare difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated
\nin the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.<\/p>\n
\u00a0<\/p>\n
A
\nfurther list and description of risks and uncertainties can be found in documents filed with the Securities and Exchange Commission (\u201cSEC\u201d)
\nby the Company and other documents that we may file or furnish with the SEC, which you are encouraged to read. Any forward-looking statement
\nmade by us in this press release is based only on information currently available to the Company and speaks only as of the date on which
\nit is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may
\nbe made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.<\/p>\n
\u00a0<\/p>\n
Investor
\nRelations Contact<\/p>\n
\u00a0<\/p>\n
Philip
\nCarlson<\/p>\n
KCSA
\nStrategic Communications<\/p>\n
Phone:
\n212.896.1233<\/p>\n
Email:
\nAlps@kcsa.com<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"\u00a0 \u00a0 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 \u00a0 FORM 6-K \u00a0 REPORT OF FOREIGN…\n","protected":false},"author":2,"featured_media":90967,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[16],"tags":[50,11411,45885,45886,45883,45884,6311,24096],"class_list":["post-90966","post","type-post","status-publish","format-standard","has-post-thumbnail","category-alps","tag-alps","tag-alps-group-inc","tag-malaysia-biotech","tag-organoids-market","tag-patient-derived-organoid","tag-pdo-program","tag-personalized-cancer-treatment","tag-precision-oncology"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116803503855608545","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/90966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=90966"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/90966\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/90967"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=90966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=90966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=90966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}